EP1563073A4 - Proteinproduktionsverfahren und modifizierte zellen zur verwendung darin - Google Patents

Proteinproduktionsverfahren und modifizierte zellen zur verwendung darin

Info

Publication number
EP1563073A4
EP1563073A4 EP03739320A EP03739320A EP1563073A4 EP 1563073 A4 EP1563073 A4 EP 1563073A4 EP 03739320 A EP03739320 A EP 03739320A EP 03739320 A EP03739320 A EP 03739320A EP 1563073 A4 EP1563073 A4 EP 1563073A4
Authority
EP
European Patent Office
Prior art keywords
production methods
protein production
modified cells
cells
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03739320A
Other languages
English (en)
French (fr)
Other versions
EP1563073A2 (de
Inventor
Gisela Chiang
William Sisk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Biogen MA Inc
Original Assignee
Biogen Idec Inc
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Biogen Idec MA Inc filed Critical Biogen Idec Inc
Publication of EP1563073A2 publication Critical patent/EP1563073A2/de
Publication of EP1563073A4 publication Critical patent/EP1563073A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP03739320A 2002-06-26 2003-06-26 Proteinproduktionsverfahren und modifizierte zellen zur verwendung darin Withdrawn EP1563073A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US39173802P 2002-06-26 2002-06-26
US391738P 2002-06-26
US44049803P 2003-01-16 2003-01-16
US440498P 2003-01-16
PCT/US2003/020207 WO2004003151A2 (en) 2002-06-26 2003-06-26 Protein production methods and modified cells for use therein

Publications (2)

Publication Number Publication Date
EP1563073A2 EP1563073A2 (de) 2005-08-17
EP1563073A4 true EP1563073A4 (de) 2007-09-19

Family

ID=30003205

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03739320A Withdrawn EP1563073A4 (de) 2002-06-26 2003-06-26 Proteinproduktionsverfahren und modifizierte zellen zur verwendung darin

Country Status (5)

Country Link
EP (1) EP1563073A4 (de)
JP (2) JP2006503555A (de)
AU (2) AU2003245702A1 (de)
CA (1) CA2491212A1 (de)
WO (1) WO2004003151A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100454016B1 (ko) * 2002-01-05 2004-10-26 한국과학기술원 항예정사 유전자로 형질전환되고 ｄｈｆｒ 유전자가결핍된 신규한 ｃｈｏ 세포주, 그의 제조 방법 및 상기형질전환된 ｃｈｏ 숙주 세포를 이용한 목적단백질의 생산방법
US7531327B2 (en) * 2004-07-23 2009-05-12 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
EP2209891A1 (de) * 2007-11-13 2010-07-28 Boehringer Ingelheim Pharma GmbH & Co. KG Verbesserung des sekretionsvermögens bei wirtszellen

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1348758A1 (de) * 2002-03-28 2003-10-01 Boehringer Ingelheim Pharma GmbH & Co.KG Wirtszellen mit verbessertem Überleben und Verfahren zur Herstellung von diesen Zellen
EP1468079A1 (de) * 2002-01-05 2004-10-20 Korea Advanced Institute of Science and Technology Mit einem antiapoptotischem gen transfizierte dhfr-defiziente cho-zellinie, verfahren zur herstellung davon und verfahren zur produktion von zielprotein unter verwendung davon

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6163196A (en) * 1995-06-07 1996-12-30 Smithkline Beecham Corporation Method for obtaining receptor agonist antibodies
US6218181B1 (en) * 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1468079A1 (de) * 2002-01-05 2004-10-20 Korea Advanced Institute of Science and Technology Mit einem antiapoptotischem gen transfizierte dhfr-defiziente cho-zellinie, verfahren zur herstellung davon und verfahren zur produktion von zielprotein unter verwendung davon
EP1348758A1 (de) * 2002-03-28 2003-10-01 Boehringer Ingelheim Pharma GmbH & Co.KG Wirtszellen mit verbessertem Überleben und Verfahren zur Herstellung von diesen Zellen

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
CHIANG GISELA G ET AL: "Bcl-x(L) mediates increased production of humanized monoclonal antibodies in chinese hamster ovary cells", BIOTECHNOLOGY AND BIOENGINEERING, vol. 91, no. 7, September 2005 (2005-09-01), pages 779 - 792, XP002446137, ISSN: 0006-3592 *
FIGUEROA B ET AL: "A COMPARISON OF THE PROPERTIES OF A BCL-XL VARIANT TO THE WILD-TYPE ANTI-APOPTOSIS INHIBITOR IN MAMMALIAN CELL CULTURES", METABOLIC ENGINEERING, ACADEMIC PRESS,, US, vol. 5, no. 4, October 2003 (2003-10-01), pages 230 - 245, XP008064154, ISSN: 1096-7176 *
FUSSENEGGER M ET AL: "CONTROLLED PROLIFERATION BY MULTIGENE METABOLIC ENGINEERING ENHANCES THE PRODUCTIVITY OF CHINESE HAMSTER OVARY CELLS", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 16, no. 5, May 1998 (1998-05-01), pages 468 - 472, XP001093788, ISSN: 1087-0156 *
FUSSENEGGER M. ET AL: "Regulated overexpression of the survival factor bcl-2 in CHO cells increases viable cell density in batch culture and decreases DNA release in extended fixed-bed cultivation", CYTOTECHNOLOGY, vol. 32, no. 1, 1 January 2000 (2000-01-01), KLUWER ACADEMIC PUBLISHERS, DORDRECHT, NL, pages 45 - 61, XP002326419 *
GOSWAMI J ET AL: "Apoptosis in batch cultures of Chinese hamster ovary cells", BIOTECHNOLOGY AND BIOENGINEERING, WILEY & SONS, HOBOKEN, NJ, US, vol. 62, no. 6, 20 March 1999 (1999-03-20), pages 632 - 640, XP002326418, ISSN: 0006-3592 *
JOEL CHARBONNEAU ET AL: "Protection of hybridoma cells against apoptosis by a loop domain-deficient Bcl-xL protein", CYTOTECHNOLOGY, KLUWER ACADEMIC PUBLISHERS, DO, vol. 37, no. 1, 1 September 2001 (2001-09-01), pages 41 - 47, XP019236711, ISSN: 1573-0778 *
JUNG D. ET AL: "Inducible expression of Bcl-XL restricts apoptosis resistance to the antibody secretion phase in hybridoma cultures", BIOTECHNOLOGY AND BIOENGINEERING, vol. 79, no. 2, 21 May 2002 (2002-05-21) - 20 July 2002 (2002-07-20), pages 180 - 187 *
KIM N S ET AL: "Overexpression of bcl-2 inhibits sodium butyrate-induced apoptosis in Chinese hamster ovary cells resulting in enhanced humanized antibody production", BIOTECHNOLOGY AND BIOENGINEERING - COMBINATORIAL CHEMISTRY, WILEY, NEW YORK, NY, US, vol. 71, no. 3, 2000, pages 184 - 193, XP002208594 *
MASTRANGELO A J ET AL: "Part II. Overexpression of bcl-2 family members enhances survival of mammalian cells in response to various culture insults", BIOTECHNOLOGY AND BIOENGINEERING, WILEY & SONS, HOBOKEN, NJ, US, vol. 67, no. 5, 5 March 2000 (2000-03-05), pages 555 - 564, XP002326420, ISSN: 0006-3592 *
MASTRANGELO ALISON J ET AL: "Part I. Bcl-2 and bcl-xL limit apoptosis upon infection with alphavirus vectors", BIOTECHNOLOGY AND BIOENGINEERING, WILEY & SONS, HOBOKEN, NJ, US, vol. 67, no. 5, 5 March 2000 (2000-03-05), pages 544 - 554, XP002217633, ISSN: 0006-3592 *
MEENTS H ET AL: "Impact of coexpression and coamplification of sICAM and antiapoptosis determinants bcl-2/bcl-x(L) on productivity, cell survival, and mitochondria number in CHO-DG44 grown in suspension and serum-free media", BIOTECHNOLOGY AND BIOENGINEERING, WILEY & SONS, HOBOKEN, NJ, US, vol. 80, no. 6, 20 December 2002 (2002-12-20), pages 706 - 716, XP002251640, ISSN: 0006-3592 *
ZANGHI JAMES A ET AL: "Serum protects protein-free competent Chinese hamster ovary cells against apoptosis induced by nutrient deprivation in batch culture", BIOTECHNOLOGY AND BIOENGINEERING, vol. 64, no. 1, 5 July 1999 (1999-07-05), pages 108 - 119, XP002446136, ISSN: 0006-3592 *

Also Published As

Publication number Publication date
WO2004003151A2 (en) 2004-01-08
JP2006503555A (ja) 2006-02-02
AU2010201256A1 (en) 2010-04-22
CA2491212A1 (en) 2004-01-08
EP1563073A2 (de) 2005-08-17
JP2011004771A (ja) 2011-01-13
WO2004003151A3 (en) 2005-06-23
AU2003245702A1 (en) 2004-01-19

Similar Documents

Publication Publication Date Title
AU2003223386A8 (en) Low-power high-performance memory cell and related methods
EP1689854A4 (de) Plazentastammzellen und verwendungen davon
AU2003237788A8 (en) Electrode constructs, and related cells and methods
IL166467A0 (en) Auto-stimulating cells and method for making and using the same
EP1576088A4 (de) Dominant-negative proteine und verfahren dazu
AU2003233865A8 (en) Electrolysis cell and method
AU2003216822A8 (en) Stem cell culture
AU2002952181A0 (en) Electrolysis process and cell for use in same
EP1581637A4 (de) Materialien und verfahren mit menschlichen stammzellen
EP1479776A4 (de) Zellextrakt für die zellfreie proteinsynthese und verfahren zur herstellung davon
GB2411378B (en) Droplet-deposition related methods and appparatus
EP1563073A4 (de) Proteinproduktionsverfahren und modifizierte zellen zur verwendung darin
AU2003248694A8 (en) Methods and cells for improved production of polyketides
AU2003225010A8 (en) Protein arrays and methods of production
GB0229967D0 (en) Protein production
GB2394477B (en) Cell culture
AU2003253675A8 (en) Methods for protein analyses and protein expression in multicellular organisms and cells therefrom
GB0223860D0 (en) Polypeptide methods and means
AU2003263751A8 (en) Novel proteins and their uses
AU2003296163A1 (en) Cell cycle-controlling protein and utilization thereof
AU2003285877A8 (en) Novel proteins and their uses
GB0228538D0 (en) Protein structure and uses thereof
GB0317767D0 (en) Cell culture
GB0219777D0 (en) Cell culture
GB0210458D0 (en) Cell culture

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050118

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1081989

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20070822

17Q First examination report despatched

Effective date: 20071213

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20101014

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1081989

Country of ref document: HK